Italia markets closed

Basilea Pharmaceutica AG (0QNA.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
38,15-0,15 (-0,39%)
Alla chiusura: 06:02PM BST
Schermo intero
Chiusura precedente38,30
Aperto37,80
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno37,80 - 38,75
Intervallo di 52 settimane37,80 - 38,75
Volume2.637
Media VolumeN/D
Capitalizzazione4,116M
Beta (5 anni mensile)0,91
Rapporto PE (ttm)N/D
EPS (ttm)-0,58
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium

    Basel/Allschwil, Switzerland, September 21, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the closing of the previously announced CHF 75 million senior secured loan agreement with funds managed by Athyrium Capital Management, LP ("Athyrium"). Adesh Kaul, Chief Financial Officer of Basilea, said: “We are pleased to announce the closing of this loan agr

  • GlobeNewswire

    Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance

    Upfront and near-term milestone payments of USD 14 million Additional milestone payments of approximately USD 320 million and tiered royalties on net salesSecond oncology transaction as part of strategic refocusing on anti-infectivesFull-year 2022 revenue guidance increased, resulting in improved expected operating result and operating cash flow Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, September 20, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage b

  • GlobeNewswire

    Basilea announces sale of preclinical oncology program to Nodus Oncology

    Sale of Basilea’s novel PARG inhibitor discovery programUpfront and milestone payments of up to CHF 242 million and approximately 5% participation in net salesImportant step in implementing Basilea’s strategic refocus on anti-infectives Basel/Allschwil, Switzerland, September 08, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into